MCID: OCL022
MIFTS: 55

Ocular Melanoma

Categories: Cancer diseases, Eye diseases, Neuronal diseases, Rare diseases, Skin diseases

Aliases & Classifications for Ocular Melanoma

MalaCards integrated aliases for Ocular Melanoma:

Name: Ocular Melanoma 12 77 54 56 15 17
Intraocular Melanoma 12 54 30 6
Malignant Melanoma of Eye 74
Melanoma of the Uvea 54
Melanoma of Eye 12
Uveal Melanoma 54
Eye Melanoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1752
UMLS 74 C0558356

Summaries for Ocular Melanoma

NIH Rare Diseases : 54 Intraocular melanoma is a cancer of the pigment-producing cells (melanocytes) in the middle layer of the eye, called the uveal tract.  The uveal tract has 3 main parts: (1) the choroid (the tissue layer filled with blood vessels); (2) the ciliary body (the ring of muscle tissue that changes the size of the pupil and the shape of the lens); and (3) the iris (the colored part of the eye). Most cases (90%) of intraocular melanoma develop in the choroid, called choroidal melanoma; the ciliary body is less commonly a site of origin, and the iris is the least common.  Each manifests with different clinical features and symptoms. Treatment depends on the site of origin (choroid, ciliary body, or iris), size and location of the tumor, the age of the individual, and other factors. 

MalaCards based summary : Ocular Melanoma, also known as intraocular melanoma, is related to tumor predisposition syndrome and melanoma. An important gene associated with Ocular Melanoma is GNAQ (G Protein Subunit Alpha Q), and among its related pathways/superpathways are Human cytomegalovirus infection and Ras signaling pathway. The drugs Ranibizumab and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include eye, liver and retina, and related phenotypes are hematopoietic system and endocrine/exocrine gland

Disease Ontology : 12 An ocular cancer that has material basis in melanocytes and is located in the eye.

Wikipedia : 77 Uveal melanoma is a cancer (melanoma) of the eye involving the iris, ciliary body, or choroid... more...

Related Diseases for Ocular Melanoma

Diseases related to Ocular Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 142)
# Related Disease Score Top Affiliating Genes
1 tumor predisposition syndrome 32.8 BAP1 BRCA2
2 melanoma 31.0 CDKN2A MAGEA1 MAGEA3 MC1R NRAS
3 macular dystrophy, dominant cystoid 30.0 SERPINF1 VEGFA
4 malignant peritoneal mesothelioma 30.0 BAP1 CDKN2A
5 dysplastic nevus syndrome 29.9 BRCA2 CDKN2A
6 malignant conjunctival melanoma 29.4 GNA11 GNAQ NRAS
7 melanoma, uveal 28.5 BAP1 CDKN2A GNA11 GNAQ MAGEA1 MC1R
8 melanoma, cutaneous malignant 1 28.3 BAP1 CDKN2A GNA11 GNAQ KIT MC1R
9 posterior uveal melanoma 12.5
10 necrotic uveal melanoma 12.4
11 mixed cell uveal melanoma 12.4
12 spindle cell intraocular melanoma 12.3
13 uveal epithelioid cell melanoma 11.4
14 bap1 tumor predisposition syndrome 11.4
15 iris spindle cell melanoma 11.3
16 maxillary sinus adenoid cystic carcinoma 10.4 IL2 KIT
17 macular retinal edema 10.3
18 ovarian melanoma 10.3 KIT NRAS
19 conventional fibrosarcoma 10.3 KIT NRAS
20 malignant spindle cell melanoma 10.3 KIT NRAS
21 adenoid basal cell carcinoma 10.2 CDKN2A KIT
22 neovascular glaucoma 10.2
23 myotonic dystrophy 10.2
24 myotonia atrophica 10.2
25 peritoneum cancer 10.2 BAP1 BRCA2
26 lymphoepithelioma-like thymic carcinoma 10.2 CDKN2A KIT
27 glycogen-rich clear cell breast carcinoma 10.2 BRCA2 CDKN2A
28 depression 10.2
29 skin melanoma 10.2
30 balanoposthitis 10.2 CDKN2A IL2
31 breast giant fibroadenoma 10.2 BRCA2 CDKN2A
32 infiltrating angiolipoma 10.2 CDKN2A VEGFA
33 anxiety 10.1
34 herpes simplex 10.1
35 hypoxia 10.1
36 cervicitis 10.1 CDKN2A IL2
37 balanitis xerotica obliterans 10.1 CDKN2A VEGFA
38 acral lentiginous melanoma 10.1 CDKN2A KIT NRAS
39 melanoma metastasis 10.1
40 insulin-like growth factor i 10.0
41 hemangioma 10.0
42 uveitis 10.0
43 optic nerve disease 10.0
44 neuropathy 10.0
45 female reproductive system disease 10.0 BRCA2 CDKN2A VEGFA
46 reproductive system disease 10.0 BRCA2 CDKN2A VEGFA
47 melanocytic nevus syndrome, congenital 10.0 MC1R NRAS
48 pharynx cancer 10.0 CDKN2A KIT VEGFA
49 endocrine gland cancer 10.0 BRCA2 CDKN2A VEGFA
50 gastrointestinal system cancer 10.0 CDKN2A KIT VEGFA

Graphical network of the top 20 diseases related to Ocular Melanoma:



Diseases related to Ocular Melanoma

Symptoms & Phenotypes for Ocular Melanoma

MGI Mouse Phenotypes related to Ocular Melanoma:

47 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.29 BAP1 BRCA2 CDKN2A CIITA GNA11 GNAQ
2 endocrine/exocrine gland MP:0005379 10.28 BAP1 BRCA2 CDKN2A CIITA GNA11 GNAQ
3 immune system MP:0005387 10.26 BAP1 BRCA2 CDKN2A CIITA GNA11 GNAQ
4 behavior/neurological MP:0005386 10.23 BRCA2 CDKN2A GNA11 GNAQ IL2 KIT
5 cardiovascular system MP:0005385 10.22 BAP1 CDKN2A GNA11 GNAQ IL2 KIT
6 growth/size/body region MP:0005378 10.22 BAP1 BRCA2 CDKN2A GNA11 GNAQ IL2
7 homeostasis/metabolism MP:0005376 10.19 BAP1 BRCA2 CDKN2A CIITA GNA11 GNAQ
8 digestive/alimentary MP:0005381 10.15 BAP1 BRCA2 CDKN2A IL2 KIT NRAS
9 integument MP:0010771 10.11 BAP1 BRCA2 CDKN2A GNA11 GNAQ KIT
10 craniofacial MP:0005382 10.03 GNA11 GNAQ KIT MC1R NRAS VEGFA
11 limbs/digits/tail MP:0005371 9.98 BRCA2 GNA11 GNAQ KIT MC1R NRAS
12 neoplasm MP:0002006 9.97 BAP1 BRCA2 CDKN2A IL2 KIT MC1R
13 liver/biliary system MP:0005370 9.88 CDKN2A GNA11 IL2 KIT NRAS VEGFA
14 no phenotypic analysis MP:0003012 9.87 BAP1 CDKN2A IL2 KIT MC1R NRAS
15 normal MP:0002873 9.86 BRCA2 CIITA GNA11 GNAQ KIT NRAS
16 pigmentation MP:0001186 9.7 CDKN2A GNA11 GNAQ KIT MC1R NRAS
17 respiratory system MP:0005388 9.5 BAP1 CDKN2A GNA11 GNAQ IL2 KIT
18 skeleton MP:0005390 9.28 BRCA2 CDKN2A CIITA GNA11 GNAQ KIT

Drugs & Therapeutics for Ocular Melanoma

Drugs for Ocular Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 199)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 2,Phase 3 347396-82-1 459903
2
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 124-94-7 31307
3 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
4 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
5 glucocorticoids Phase 4,Phase 2,Phase 3,Not Applicable
6 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Not Applicable
7 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
8 Triamcinolone hexacetonide Phase 4,Phase 2,Phase 3,Not Applicable
9 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
10 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
11 Triamcinolone diacetate Phase 4,Phase 2,Phase 3,Not Applicable
12 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
13 triamcinolone acetonide Phase 4,Phase 2,Phase 3,Not Applicable
14 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
15
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
16
Bevacizumab Approved, Investigational Phase 3,Phase 2,Not Applicable 216974-75-3
17
Melphalan Approved Phase 3,Phase 2 148-82-3 460612 4053
18
Fotemustine Investigational Phase 3 92118-27-9
19 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Early Phase 1
20 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
21 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Vaccines Phase 3,Phase 2,Phase 1,Not Applicable
24 Mitogens Phase 3,Phase 2,Phase 1
25 Endothelial Growth Factors Phase 3,Phase 2
26
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
27
Tamoxifen Approved Phase 2 10540-29-1 2733526
28
Cisplatin Approved Phase 2,Phase 1 15663-27-1 2767 441203 84093
29
Sodium Citrate Approved, Investigational Phase 2 68-04-2
30
Sunitinib Approved, Investigational Phase 2,Phase 1 557795-19-4, 341031-54-7 5329102
31
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
32
Sorafenib Approved, Investigational Phase 2,Phase 1 284461-73-0 216239 406563
33
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
34
Lenalidomide Approved Phase 2 191732-72-6 216326
35
Ipilimumab Approved Phase 2,Phase 1,Early Phase 1 477202-00-9
36
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 38904 498142
37
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
38
Trametinib Approved Phase 2,Phase 1 871700-17-3 11707110
39
Sirolimus Approved, Investigational Phase 2,Not Applicable 53123-88-9 46835353 5284616 6436030
40
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
41
Pasireotide Approved Phase 2 396091-73-9 9941444
42
Somatostatin Approved, Investigational Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
43
Everolimus Approved Phase 2,Not Applicable 159351-69-6 70789204 6442177
44
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
45
Sargramostim Approved, Investigational Phase 2,Phase 1 123774-72-1, 83869-56-1
46 Ethiodized oil Approved, Investigational Phase 2 8008-53-5
47
Peginterferon alfa-2b Approved Phase 2 215647-85-1, 99210-65-8
48
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
49
Aluminum sulfate Approved Phase 2 10043-01-3
50
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2

Interventional clinical trials:

(show top 50) (show all 171)
# Name Status NCT ID Phase Drugs
1 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
2 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Unknown status NCT02379000 Phase 4 Triamcinolone Acetonide
3 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
4 Treatment Of Radiation Retinopathy Trial Unknown status NCT00811200 Phase 2, Phase 3 ranibizumab;triamcinolone acetonide
5 Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Completed NCT01974752 Phase 3 75mg selumetinib;placebo;Dacarbazine
6 Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma Completed NCT00324727 Phase 3 melphalan;regional chemotherapy;systemic chemotherapy
7 Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma Recruiting NCT02678572 Phase 3
8 Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma Recruiting NCT01983748 Phase 3
9 The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases Recruiting NCT01785316 Phase 3
10 Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma Active, not recruiting NCT02843386 Phase 3 Adjuvant chemotherapy by Fotemustin
11 Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma Not yet recruiting NCT03172299 Phase 3 Aflibercept Injection;False injection
12 Vaccine Therapy in Treating Patients With Melanoma of the Eye Terminated NCT00036816 Phase 3
13 Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma Terminated NCT00110123 Phase 3 fotemustine;isolated perfusion
14 Study of Metastatic Ocular Melanoma Unknown status NCT00168870 Phase 2 Gemcitabine;Treosulfan
15 Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma Unknown status NCT00489944 Phase 2 cisplatin;sunitinib malate;tamoxifen citrate
16 Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye Unknown status NCT01217398 Phase 2 temozolomide
17 Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis Unknown status NCT02936388 Phase 2
18 A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma Unknown status NCT01377025 Phase 2 Placebo;Sorafenib;Sorafenib
19 A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma Unknown status NCT01551459 Phase 2 Dacarbazine;Sunitinib
20 STA-9090(Ganetespib) in Metastatic Ocular Melanoma Completed NCT01200238 Phase 2 STA-9090
21 Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma Completed NCT00109005 Phase 2 Revlimid
22 THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease Completed NCT01355120 Phase 2 Ipilimumab
23 A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma Completed NCT00062933 Phase 2
24 Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye Completed NCT00020475 Phase 2 gp100 antigen;interleukin-2;MART-1 antigen;Montanide ISA-51
25 Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma Completed NCT00003802 Phase 2 pyrazoloacridine
26 Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma Completed NCT00085306 Phase 2
27 Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Completed NCT01143402 Phase 2 Dacarbazine;Selumetinib;Temozolomide
28 Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye Completed NCT01413191 Phase 2
29 Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye Completed NCT00329641 Phase 2 carboplatin;paclitaxel;sorafenib tosylate
30 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery Completed NCT00738361 Phase 2 nab-paclitaxel
31 Taxoprexin® Treatment for Advanced Eye Melanoma Completed NCT00244816 Phase 2 Taxoprexin
32 Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma Completed NCT01979523 Phase 2 Trametinib;Uprosertib
33 Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma Completed NCT01034787 Phase 2 CP-675,206
34 RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma Completed NCT01252251 Phase 2 RAD001 (Everolimus) and Pasireotide (SOM230) LAR
35 Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma Completed NCT00506142 Phase 2 Marqibo® (vincristine sulfate liposomes injection)
36 Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance Completed NCT01100528 Phase 2 dacarbazine
37 Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma Completed NCT02363283 Phase 2 Glembatumumab Vedotin
38 Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination Completed NCT02517736 Phase 2 Sorafenib at a dose of 800 mg / day
39 Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF Completed NCT00661622 Phase 2 GM-CSF
40 Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma Completed NCT00003339 Phase 2
41 Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma Completed NCT00084656 Phase 2
42 Vaccine Therapy in Treating Patients With Metastatic Melanoma Completed NCT00334776 Phase 2
43 PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma Completed NCT00238329 Phase 2 thalidomide
44 Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma Completed NCT00027742 Phase 2 temozolomide
45 Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery Completed NCT00089206 Phase 2
46 Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma Completed NCT00089219 Phase 1, Phase 2
47 Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma Completed NCT00072345 Phase 2 lomustine;temozolomide;thalidomide
48 Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma Completed NCT00032045 Phase 2
49 Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma Completed NCT00031733 Phase 2 alum adjuvant
50 Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma Completed NCT00005815 Phase 1, Phase 2 temozolomide;thalidomide

Search NIH Clinical Center for Ocular Melanoma

Genetic Tests for Ocular Melanoma

Genetic tests related to Ocular Melanoma:

# Genetic test Affiliating Genes
1 Intraocular Melanoma 30

Anatomical Context for Ocular Melanoma

MalaCards organs/tissues related to Ocular Melanoma:

42
Eye, Liver, Retina, Skin, Testes, Bone, Myeloid

The Foundational Model of Anatomy Ontology organs/tissues related to Ocular Melanoma:

20
The Eye

Publications for Ocular Melanoma

Articles related to Ocular Melanoma:

(show top 50) (show all 413)
# Title Authors Year
1
Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study. ( 30924738 )
2019
2
Dosimetric comparison of circular Eye Physics and Collaborative Ocular Melanoma Study plaques to treat uveal melanoma. ( 30797699 )
2019
3
Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems' Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial. ( 30767147 )
2019
4
Outcomes of cataract surgery in eyes with ocular melanoma treated with iodine-125 brachytherapy. ( 29703285 )
2018
5
Headache with Aura: A case report of ocular melanoma. ( 30135025 )
2018
6
Tetrac Delayed the Onset of Ocular Melanoma in an Orthotopic Mouse Model. ( 30671022 )
2018
7
Can CT imaging improve targeting accuracy in clip-based proton therapy of ocular melanoma? ( 30566923 )
2018
8
The Patient's Experience of Ocular Melanoma in the US: A Survey of the Ocular Melanoma Foundation. ( 30320098 )
2018
9
Is Collaborative Ocular Melanoma Study (COMS) still relevant? ( 30249817 )
2018
10
Ocular Melanoma Recurrence Presenting as Cholestatic Jaundice due to Periampullary Area Metastases. ( 30134646 )
2018
11
Hepatic artery infusion of melphalan in patients with liver metastases from ocular melanoma. ( 29878390 )
2018
12
Gamma irradiation of ocular melanoma and lymphoma cells in the presence of gold nanoparticles: in vitro study. ( 29707895 )
2018
13
MRI-based treatment planning and dose delivery verification for intraocular melanoma brachytherapy. ( 28818442 )
2018
14
Visualization and Quantitative 3D Analysis of Intraocular Melanoma and Its Vascularization in a Hamster Eye. ( 29364141 )
2018
15
Health-related quality of life during trans-arterial chemoembolization with drug-eluting beads loaded with doxorubicin (DEBDOX) for unresectable hepatic metastases from ocular melanoma. ( 28754534 )
2017
16
Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Ocular Melanoma as a Tool to Predict Metastatic Potential. ( 28448404 )
2017
17
PRL-3/PTP4A3 phosphatase regulates integrin β1 in adhesion structures during migration of human ocular melanoma cells. ( 28284838 )
2017
18
Reproducibility of a Noninvasive System for Eye Positioning and Monitoring in Stereotactic Radiotherapy of Ocular Melanoma. ( 28168935 )
2017
19
Ocular melanoma-when you have seen one, you have not seen them all: a clinical outcome study from the Surveillance, Epidemiology and End Results (SEER) database (1973-2012). ( 28115829 )
2017
20
Comment on "Milham & Stetzer (2016) Tumor-specific frequencies and ocular melanoma." Electromag Biol Med http://dx.doi.org/10.1080/15368378.2016.1234390. ( 27715332 )
2017
21
Tumor-specific frequencies and ocular melanoma. ( 27552371 )
2017
22
Clinical experience of stereotactic radiosurgery at a linear accelerator for intraocular melanoma. ( 28520637 )
2017
23
Imaging of ocular melanoma metastasis. ( 27168029 )
2016
24
Metastatic melanoma after 23 years of primary ocular melanoma. ( 27881589 )
2016
25
Head and neck melanoma (excluding ocular melanoma): United Kingdom National Multidisciplinary Guidelines. ( 27841141 )
2016
26
EPIDEMIOLOGICAL ANALYSIS OF OCULAR MELANOMA IN UNIVERSITY CLINIC CENTER IN TUZLA, BOSNIA AND HERZEGOVINA. ( 27698609 )
2016
27
A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib. ( 27520988 )
2016
28
Metastatic ocular melanoma to the liver exhibits infiltrative and nodular growth patterns. ( 27476775 )
2016
29
Investigating the dosimetric impact of seed location uncertainties in Collaborative Ocular Melanoma Study-based eye plaques. ( 27475484 )
2016
30
Feasibility of Proton Beam Therapy for Ocular Melanoma Using a Novel 3D Treatment Planning Technique. ( 27084652 )
2016
31
Overexpression of hepatocyte growth factor and an oncogenic CDK4 variant in mice alters corneal stroma morphology but does not lead to spontaneous ocular melanoma. ( 26731561 )
2016
32
The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism. ( 26655090 )
2016
33
Intravitreally Injected HCmel12 Melanoma Cells Serve as a Mouse Model of Tumor Biology of Intraocular Melanoma. ( 25658144 )
2016
34
Metastatic Ocular Melanoma Presenting as a Heart-Compressing Mediastinal Mass. ( 26434443 )
2015
35
A challenging case of ocular melanoma. ( 26429178 )
2015
36
Nationwide Incidence of Ocular Melanoma in South Korea by Using the National Cancer Registry Database (1999-2011). ( 26207308 )
2015
37
Low thyroid hormone levels improve survival in murine model for ocular melanoma. ( 25868390 )
2015
38
Dynamic contrast-enhanced MRI of ocular melanoma. ( 25714038 )
2015
39
Diffusion-weighted magnetic resonance imaging for predicting and detecting the response of ocular melanoma to proton beam therapy: initial results. ( 25578783 )
2015
40
Heterogeneous dose calculations for Collaborative Ocular Melanoma Study eye plaques using actual seed configurations and Task Group Report 43 formalism. ( 25533415 )
2015
41
Inhibition of tumor growth by β-elemene through downregulation of the expression of uPA, uPAR, MMP-2, and MMP-9 in a murine intraocular melanoma model. ( 25405459 )
2015
42
Cost-effectiveness of proton beam therapy for intraocular melanoma. ( 25993284 )
2015
43
Secondary neutron doses in proton therapy treatments of ocular melanoma and craniopharyngioma. ( 24222710 )
2014
44
Isolated hepatic perfusion for ocular melanoma metastasis: registry data suggests a survival benefit. ( 24141377 )
2014
45
Effects of defining realistic compositions of the ocular melanoma on proton therapy. ( 25599060 )
2014
46
Evidence-based integration of selective internal radiation therapy into the management of ocular melanoma liver metastases. ( 25478778 )
2014
47
Method for verifying the air kerma strength of I-125 plaques for the treatment of ocular melanoma. ( 25207419 )
2014
48
Ocular melanoma and the BAP1 hereditary cancer syndrome: implications for the dermatologist. ( 24697775 )
2014
49
Progression of ocular melanoma metastasis to the liver: the 2012 Zimmerman lecture. ( 23392528 )
2013
50
The Collaborative Ocular Melanoma Study, mortality by therapeutic approach, age and tumor size. ( 24069782 )
2013

Variations for Ocular Melanoma

ClinVar genetic disease variations for Ocular Melanoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 GNAQ NM_002072.4(GNAQ): c.626A> T (p.Gln209Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913492 GRCh37 Chromosome 9, 80409488: 80409488
2 GNAQ NM_002072.4(GNAQ): c.626A> T (p.Gln209Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913492 GRCh38 Chromosome 9, 77794572: 77794572
3 GNAQ NM_002072.4(GNAQ): c.626A> C (p.Gln209Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913492 GRCh37 Chromosome 9, 80409488: 80409488
4 GNAQ NM_002072.4(GNAQ): c.626A> C (p.Gln209Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913492 GRCh38 Chromosome 9, 77794572: 77794572
5 GNA11 NM_002067.4(GNA11): c.626A> C (p.Gln209Pro) single nucleotide variant Pathogenic/Likely pathogenic rs1057519742 GRCh37 Chromosome 19, 3118942: 3118942
6 GNA11 NM_002067.4(GNA11): c.626A> C (p.Gln209Pro) single nucleotide variant Pathogenic/Likely pathogenic rs1057519742 GRCh38 Chromosome 19, 3118944: 3118944
7 GNA11 NM_002067.4(GNA11): c.626A> T (p.Gln209Leu) single nucleotide variant Pathogenic/Likely pathogenic rs1057519742 GRCh37 Chromosome 19, 3118942: 3118942
8 GNA11 NM_002067.4(GNA11): c.626A> T (p.Gln209Leu) single nucleotide variant Pathogenic/Likely pathogenic rs1057519742 GRCh38 Chromosome 19, 3118944: 3118944
9 GNAQ NM_002072.4(GNAQ): c.625_626delCAinsTT (p.Gln209Leu) indel Likely pathogenic rs1057519853 GRCh37 Chromosome 9, 80409488: 80409489
10 GNAQ NM_002072.4(GNAQ): c.625_626delCAinsTT (p.Gln209Leu) indel Likely pathogenic rs1057519853 GRCh38 Chromosome 9, 77794572: 77794573

Cosmic variations for Ocular Melanoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM52969 GNA11 eye,uveal tract,malignant melanoma,ring c.626A>T p.Q209L 19:3118944-3118944 0
2 COSM6498619 BAP1 eye,uveal tract,malignant melanoma,ring c.306C>G p.N102K 3:52408027-52408027 0

Expression for Ocular Melanoma

Search GEO for disease gene expression data for Ocular Melanoma.

Pathways for Ocular Melanoma

Pathways related to Ocular Melanoma according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.69 CDKN2A GNA11 GNAQ NRAS VEGFA
2
Show member pathways
12.49 GNAQ KIT NRAS VEGFA
3
Show member pathways
12.43 GNA11 GNAQ NRAS VEGFA
4
Show member pathways
12.4 BRCA2 CDKN2A KIT NRAS VEGFA
5 12.27 CIITA IL2 KIT MAGEA3
6 11.95 BRCA2 CDKN2A GNA11 GNAQ IL2 KIT
7
Show member pathways
11.8 GNA11 GNAQ NRAS
8
Show member pathways
11.71 GNA11 GNAQ VEGFA
9 11.55 GNA11 GNAQ IL2
10 11.44 GNA11 GNAQ NRAS
11 11.42 GNA11 GNAQ IL2 NRAS
12 11.2 CDKN2A NRAS VEGFA
13 10.96 GNA11 GNAQ NRAS
14 10.91 GNA11 GNAQ NRAS
15 10.81 GNAQ NRAS

GO Terms for Ocular Melanoma

Biological processes related to Ocular Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 action potential GO:0001508 9.46 GNA11 GNAQ
2 G protein-coupled acetylcholine receptor signaling pathway GO:0007213 9.43 GNA11 GNAQ
3 developmental pigmentation GO:0048066 9.4 GNA11 KIT
4 somatic stem cell division GO:0048103 9.37 CDKN2A KIT
5 phototransduction, visible light GO:0007603 9.32 GNA11 GNAQ
6 entrainment of circadian clock GO:0009649 9.26 GNA11 GNAQ
7 positive regulation of protein kinase C signaling GO:0090037 9.16 MC1R VEGFA
8 positive regulation of endothelial cell proliferation GO:0001938 9.13 NRAS PDCD6 VEGFA
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 8.8 IL2 KIT VEGFA

Molecular functions related to Ocular Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.8 BAP1 BRCA2 CDKN2A CIITA GNAQ IL2
2 GTP binding GO:0005525 9.56 CIITA GNA11 GNAQ NRAS
3 G-protein beta/gamma-subunit complex binding GO:0031683 9.32 GNA11 GNAQ
4 guanyl nucleotide binding GO:0019001 9.16 GNA11 GNAQ
5 type 2A serotonin receptor binding GO:0031826 8.62 GNA11 GNAQ

Sources for Ocular Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....